Short Interest in Avanos Medical, Inc. (NYSE:AVNS) Drops By 39.6%

Posted by George Bondi on May 19th, 2026

Avanos Medical, Inc. (NYSE:AVNS – Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 1,211,005 shares, a decrease of 39.6% from the April 15th total of 2,004,529 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average trading volume of 1,609,614 shares, the days-to-cover ratio is currently 0.8 days.

Avanos Medical Stock Up 0.1%

AVNS stock traded up $0.02 during mid-day trading on Monday, reaching $24.73. 849,559 shares of the company traded hands, compared to its average volume of 1,242,821. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -15.36 and a beta of 1.58. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $24.91. The firm’s 50 day moving average price is $18.75 and its 200 day moving average price is $14.66.

Avanos Medical (NYSE:AVNS – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. As a group, equities research analysts predict that Avanos Medical will post 1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Avanos Medical by 1,596,514.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock worth $167,287,000 after buying an additional 14,895,480 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Avanos Medical by 28.0% in the 4th quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock worth $35,936,000 after purchasing an additional 700,000 shares during the period. State Street Corp raised its holdings in shares of Avanos Medical by 2.8% in the 4th quarter. State Street Corp now owns 1,954,785 shares of the company’s stock worth $21,952,000 after purchasing an additional 53,523 shares during the period. Geode Capital Management LLC raised its holdings in shares of Avanos Medical by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock worth $12,180,000 after purchasing an additional 16,980 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Avanos Medical by 20.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock worth $11,687,000 after purchasing an additional 176,716 shares during the period. Institutional investors own 95.17% of the company’s stock.

Analyst Ratings Changes

AVNS has been the topic of several research analyst reports. Zacks Research lowered shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Weiss Ratings upgraded Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Sell rating, According to MarketBeat, Avanos Medical currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Avanos Medical

Avanos Medical Company Profile

(Get Free Report)

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.